Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
- 주제(키워드) Alternative pricing approaches , cancer medicines , europe , managed entry agreements , multicriteria decision analyses , minimum effectiveness criteria , payers , transparent pricing approaches , tiered pricing approaches
- 주제(기타) Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy
- 설명문(일반) [Godman, Brian; Gustafsson, Lars L.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Pharmacol, Stockholm, Sweden; [Godman, Brian; Timoney, Angela; Kwon, Hye-Young; Kurdi, Amanj; Vella Bonanno, Patricia] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Div Pharmacoepidemiol, Glasgow, Lanark, Scotland; [Godman, Brian; Kurdi, Amanj; Meyer, Johanna C.] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Div Publ Hlth Pharm & Management, Pretoria, South Africa; [Godman, Brian] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia; [Hill, Andrew] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England; [Simoens, Steven] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium; [Selke, Gisbert; Langner, Irene] Wissenschaftl Inst AOK WIdO, Berlin, Germany; [Selke Krulichova, Iva] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biophys, Hradec Kralove, Kralove, Czech Republic; [Zampirolli Dias, Carolina; Da Silva, Wania Cristina] Fed Univ Minas Gerais UFMG, Postgrad Program Med & Pharmaceut Serv, Fac Pharm, Belo Horizonte, MG, Brazil; [Zampirolli Dias, Carolina] SUS Collaborating Ctr Technol Assessment & Excell, Belo Horizonte, MG, Brazil; [Martin, Antony P.] Fac Hlth & Life Sci, Liverpool, Merseyside, England; [Martin, Antony P.] QC Med, York, N Yorkshire, England; [Oortwijn, Wija] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands; [Timoney, Angela] NHS Lothian, Edinburgh, Midlothian, Scotland; [Voncina, Luka] Fac Hlth Studies, Rijeka, Croatia; [Kwon, Hye-Young] Mokwon Univ, Div Biol & Publ Hlth, Daejeon, South Korea; [Gulbinovic, Jolanta] Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Pathol Forens Med & Pharmacol, Vilnius, Lithuania; [Da Silva, Wania Cristina] Fundacao Oswaldo Cruz, FIOCRUZ, Data & Knowledge Integrat Ctr Hlth CIDACS, Salvador, BA, Brazil; [Bochenek, Tomasz] Jagiellonian Univ Med Coll, Fac Hlth Sci, Dept Nutr & Drug Res, Krakow, Poland; [Allocati, Eleonora] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy; [Kurdi, Amanj] Hawler Med Univ, Coll Pharm, Dept Pharmacol, Erbil, Iraq; [Ogunleye, Olayinka O.] Lagos State Univ, Coll Med, Dept Pharmacol Therapeut & Toxicol, Lagos, Nigeria; [Ogunleye, Olayinka O.] Lagos State Univ, Teaching Hosp, Dept Med, Lagos, Nigeria; [Hoxha, Iris] Univ Med, Fac Med, Dept Pharm, Tirana, Albania; [Malaj, Admir] Univ Med, Tirana, Albania; [Hierlander, Christian; Sauermann, Robert] Federat Social Insurances, Dept Pharmaceut Affairs, Vienna, Austria; [Hamelinck, Wouter] Stat Dept, Brussels, Belgium; [Petrova, Guenka] Med Univ Sofia, Dept Social Pharm & Pharmacoecon, Fac Pharm, Sofia, Bulgaria; [Laius, Ott] State Agcy Med, Tartu, Estonia; [Yfantopoulos, John] Sch Natl & Kapodistrian Univ Athens, Athens, Greece; [Joppi, Roberta] Azienda Sanit Locale Verona, Pharmaceut Drug Dept, Verona, Italy; [Jakupi, Arianit] UBT, Higher Educ Inst, Fac Pharm, Prishtina, Kosovo; [Greiciute-Kuprijanov, Ieva] Minist Hlth Republ Lithuania, Dept Pharm, Vilnius, Lithuania; [Piepenbrink, Jf (Hans); de Valk, Vincent] Natl Hlth Care Inst ZIN, XH, Diemen, Netherlands; [Wladysiuk, Magdalene] HTA Consulting, Krakow, Poland; [Markovic-Pekovic, Vanda] Univ Banja Luka, Dept Social Pharm, Fac Med, Banja Luka, Bosnia & Herceg; [Mardare, Ileana] Carol Davila Univ Med & Pharm Bucharest, Fac Med Publ Hlth & Management, Bucharest, Romania; [Furst, Jurij] Hlth Insurance Inst, Ljubljana, Slovenia; [Tomek, Dominik] Slovak Med Univ Bratislava, Fac Med, Bratislava, Slovakia; [Obach Cortadellas, Merce; Zara, Corinne; Pontes, Caridad] Catalan Hlth Serv, Drug Dept, Barcelona, Spain; [Pontes, Caridad] Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain; [McTaggart, Stuart] Publ Hlth Scotland, Edinburgh, Midlothian, Scotland; [Laba, Tracey-Lea] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia; [Melien, Oyvind] Norwegian Inst Publ Hlth, Reviews & Hlth Technol Assessments, Oslo, Norway; [Wong-Rieger, Durhane] Canadian Org Rare Disorders, Inst Populat Hlth, Hlth Data Sci, Toronto, ON, Canada; [Bae, SeungJin] Ewha Womans Univ, Coll Pharm, Seoul, South Korea; [Hill, Ruaraidh] Univ Liverpool, Inst Populat Hlth, Hlth Data Sci, Liverpool Reviews & Implementat Grp, Whelan Bldg, Liverpool, Merseyside, England
- 등재 SCIE, SSCI, SCOPUS
- 발행기관 TAYLOR & FRANCIS LTD
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000183429
- 본문언어 영어
- Published As http://dx.doi.org/10.1080/14737167.2021.1884546
초록/요약
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
more